The recent availability of dalfampridine has surprisingly caused some confusion among patients with multiple sclerosis (MS). A few of my colleagues report that some of their MS patients who are taking dalfampridine refer to it as "my MS medicine” and believe that they no longer need to take their disease-modifying therapies (DMTs). To MS healthcare providers, the difference between agents intended to modify the disease process and those intended to treat specific symptoms seems obvious enough. However, the confusion that has arisen makes it clear that this difference may not be as obvious to our patients.
Featured Content
Editorials
Clearing Up Patient Confusion About Dalfampridine (Ampyra®): A Teachable Moment
Journal Articles
Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis
The aim of this study was to estimate the influence of tobacco smoking and Swedish snuff use on the risk of developing multiple sclerosis (MS).
CME Activities
MS eJournal Club
DIME eJournal Club is CME/CE-certified site for physicians and healthcare professionals. Each month, renowned experts in a range of specialties discuss disease diagnosis, treatment, and management from the perspective of recent articles in peer-reviewed journals. Select your specialty and find live and enduring CME/CE-certified activities designed with the clinician in mind.
Expert Q&As
We encourage you to submit your questions on multiple sclerosis treatment and care to our Steering Committee. We post selected questions and corresponding answers.
- Q. Is there any evidence that marijuana alleviates MS symptoms? Get the Answer
- Q. Are MRI measures associated with cognitive impairment in patients with MS? Get the Answer
Slide Library
Reconsidering Treatment in Suboptimal Responders and Treatment Failure
Michael K. Racke, MD Chairman
Department of Neurology
The Ohio State University College of Medicine
The Ohio State University Medical Center
Columbus, Ohio
| Noteworthy in MS News |
|
